SARIMED: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
SARIMED
Largest movements
- Receivables within one year -€7,173
down €7,173 (-74.9%), from €9,583 to €2,409
- Cash +€828
up €828 (+6.2%), from €13,447 to €14,275
mainly Receivables within one year (+€7,173)
- Profit (loss) carried forward -€3,971
down €3,971 (-48.4%), from €8,198 to €4,227
- Trade debts -€2,374
no longer reported in 2025 (was €2,374)
- Gross operating margin -€7,808
down €7,808, from €5,773 to -€2,035
- Taxes +€2,315
new in 2025: €2,315
- Financial income +€562
new in 2025: €562
- Financial charges -€101
down €101 (-35.5%), from €284 to €183
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €23,029 | €16,684 | -€6,345 | -27.6% |
| Current assets | 29/58 | €23,029 | €16,684 | -€6,345 | -27.6% |
| Amounts receivable within one year | 40/41 | €9,583 | €2,409 | -€7,173 | -74.9% |
| Other amounts receivable | 41 | €9,583 | €2,409 | -€7,173 | -74.9% |
| Cash at bank and in hand | 54/58 | €13,447 | €14,275 | +€828 | +6.2% |
| Total equity and liabilities | 10/49 | €23,029 | €16,684 | -€6,345 | -27.6% |
| Equity | 10/15 | €20,655 | €16,684 | -€3,971 | -19.2% |
| Contributions | 10/11 | €12,457 | €12,457 | = | 0.0% |
| Outside capital | 11 | €12,457 | €12,457 | = | 0.0% |
| Other | 1109/19 | €12,457 | €12,457 | = | 0.0% |
| Profit (loss) carried forward | 14 | €8,198 | €4,227 | -€3,971 | -48.4% |
| Amounts payable | 17/49 | €2,374 | - | -€2,374 | |
| Amounts payable within one year | 42/48 | €2,374 | - | -€2,374 | |
| Trade debts | 44 | €2,374 | - | -€2,374 | |
| Suppliers | 440/4 | €2,374 | - | -€2,374 | |
| Gross operating margin | 9900 | €5,773 | -€2,035 | -€7,808 | |
| Operating profit (loss) | 9901 | €5,773 | -€2,035 | -€7,808 | |
| Financial income | 75/76B | - | €562 | +€562 | |
| Recurring financial income | 75 | - | €562 | +€562 | |
| Financial charges | 65/66B | €284 | €183 | -€101 | -35.5% |
| Recurring financial charges | 65 | €284 | €183 | -€101 | -35.5% |
| Profit (loss) for the period before taxes | 9903 | €5,489 | -€1,656 | -€7,145 | |
| Income taxes | 67/77 | - | €2,315 | +€2,315 | |
| Profit (loss) for the period | 9904 | €5,489 | -€3,971 | -€9,460 | |
| Profit (loss) for the period to be appropriated | 9905 | €5,489 | -€3,971 | -€9,460 |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 4 October 2026 via checked.be.